Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

• Egile Nagusiak: Michal Pochopien (Egilea), Annette Beiderbeck (Egilea), Phil McEwan (Egilea), Richard Zur (Egilea), Mondher Toumi (Egilea), Samuel Aballéa (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2019-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascular endothelial growth factor inhibitors (...